ANCC PMHNP ACTUAL EXAM 2025/2026
Full Questions and Correct Answers Already Passed | Psychiatric Mental Health Nurse
Practitioner | ANCC Board Certification
Overview
This 2025/2026 validated resource contains the complete ANCC PMHNP certification
package with actual exam questions and verified correct answers. Essential for
psychiatric mental health nurse practitioners preparing for ANCC board certification and
demonstrating advanced psychiatric competency.
Key Features
✓ Actual ANCC Certification Questions
✓ Verified Correct Answers
✓ Updated 2025/2026 Psychiatric Standards
✓ Comprehensive Mental Health Coverage
✓ Board-Aligned Content Specifications
Assessment Components
175 Questions with Verified Correct Answers
Core Content Areas
Psychopharmacology & Neurobiology (30 Questions)
Psychotherapeutic Modalities (28 Questions)
Diagnosis & Assessment (25 Questions)
Clinical Management & Treatment (24 Questions)
Legal/Ethical Considerations (22 Questions)
Special Populations (22 Questions)
Health Promotion & Prevention (24 Questions)
Answer Format
Verified correct answers in bold green with:
Evidence-based treatment rationales
Diagnostic reasoning pathways
Medication management justifications
Therapeutic intervention explanations
🔹
Critical Updates 2025/2026
🔹
NEW - Updated psychopharmacology guidelines
🔹
UPDATED - Diagnostic assessment tools
REVISED - Telehealth practice standards
🔹 MODIFIED - Integrated care models
,Study Materials Include
✓ Psychopharmacology reference guides
✓ Diagnostic criteria charts
✓ Treatment algorithm references
✓ Legal/ethical decision trees
Assessment Features
✓ Timed board simulation
✓ Performance analytics by domain
✓ Customized competency recommendations
✓ Knowledge domain tracking
Psychopharmacology & Neurobiology (Questions 1–30)
Question 1: A 34-year-old female with treatment-resistant depression has failed SSRIs and
SNRIs. The PMHNP considers augmentation. Which agent has the strongest evidence for
adjunctive use in MDD per APA guidelines?
A) Lithium
B) Aripiprazole
C) T3 (liothyronine)
D) Buspirone
Rationale: FDA-approved adjunct; D2 partial agonist enhances prefrontal dopamine. STAR*D
trial; APA Practice Guideline for MDD.
Question 2: A 28-year-old male with schizophrenia on risperidone 6 mg/day develops
galactorrhea and amenorrhea. Labs: prolactin 120 ng/mL. First-line intervention?
A) Increase dose
B) Switch to aripiprazole
C) Add cabergoline
D) Continue monitoring
Rationale: Prolactin-sparing atypical; D2 partial agonism. ANCC Psychopharm.
Question 3: Mechanism of action of bupropion in depression and smoking cessation:
A) 5-HT reuptake
B) NE and DA reuptake inhibition
C) Alpha-2 antagonism
D) NMDA antagonism
Rationale: NDRI; minimal sexual side effects. Stahl’s Essential Psychopharmacology.
Question 4: A 45-year-old with bipolar I mania is on lithium 1200 mg/day. Serum level: 1.4
mEq/L. Symptoms: tremor, confusion, ataxia. Immediate action?
A) Increase dose
,B) Hold lithium, IV hydration, check renal function
C) Add valproate
D) Monitor only
Rationale: Toxicity >1.5 mEq/L; neurotoxicity. APA Bipolar Guideline.
Question 5: Clozapine monitoring: Absolute requirement before initiation and weekly for
6 months?
A) ECG
B) ANC (absolute neutrophil count)
C) LFTs
D) Lipid panel
Rationale: Agranulocytosis risk (0.8%); REMS program. FDA.
Question 6: A client on venlafaxine 300 mg/day reports BP 158/98 mmHg. Next step?
A) Discontinue immediately
B) Reduce dose, add antihypertensive if needed
C) Switch to SSRI
D) No action
Rationale: Dose-dependent hypertension; monitor BP. SNRI class effect.
Question 7: First-pass effect explains lower bioavailability of which drug when taken orally?
A) Lorazepam
B) Amitriptyline
C) Fluoxetine
D) Aripiprazole
Rationale: TCA; hepatic metabolism. Pharmacokinetics.
Question 8: A 19-year-old with ADHD starts methylphenidate. Contraindication?
A) Tics
B) Structural cardiac defect
C) Anxiety
D) Insomnia
Rationale: Sudden death risk; AHA screening. AACAP.
Question 9: Half-life of fluoxetine and norfluoxetine requires how long for full washout?
A) 1 week
B) 4–6 weeks
C) 24 hours
D) 3 days
Rationale: Longest half-life SSRI; drug interaction risk. ANCC.
Question 10: Black box warning for varenicline:
A) Seizure
, B) Neuropsychiatric symptoms (suicidality, aggression)
C) QT prolongation
D) Hepatotoxicity
Rationale: Nicotinic agonist; monitor mood. FDA.
Question 11: Paliperidone is the major active metabolite of:
A) Olanzapine
B) Risperidone
C) Quetiapine
D) Ziprasidone
Rationale: 9-hydroxyrisperidone; once-monthly IM. Psychopharm.
Question 12: Serotonin syndrome triad:
A) Bradycardia, hypotension, miosis
B) Hyperthermia, rigidity, altered mental status
C) Hyporeflexia, dry skin
D) Diarrhea only
Rationale: SSRI + MAOI; Hunter criteria. DSM-5-TR.
Question 13: CYP450 2D6 poor metabolizer increases risk of side effects with:
A) Citalopram
B) Paroxetine
C) Sertraline
D) Escitalopram
Rationale: Strong 2D6 inhibitor; dose adjustment. CPIC.
Question 14: Long-acting injectable with lowest risk of post-injection delirium/sedation
syndrome?
A) Risperidone (Risperdal Consta)
B) Aripiprazole lauroxil (Aristada)
C) Olanzapine pamoate (Zyprexa Relprevv)
D) Paliperidone palmitate (Invega Sustenna)
Rationale: No REMS monitoring required. FDA.
Question 15: Naltrexone mechanism in alcohol use disorder:
A) Dopamine agonist
B) Mu-opioid receptor antagonist
C) GABA enhancer
D) Glutamate modulator
Rationale: Reduces craving; COMBINE study. ASAM.
Question 16: Akathisia is most associated with which receptor blockade?
A) 5-HT2A
Full Questions and Correct Answers Already Passed | Psychiatric Mental Health Nurse
Practitioner | ANCC Board Certification
Overview
This 2025/2026 validated resource contains the complete ANCC PMHNP certification
package with actual exam questions and verified correct answers. Essential for
psychiatric mental health nurse practitioners preparing for ANCC board certification and
demonstrating advanced psychiatric competency.
Key Features
✓ Actual ANCC Certification Questions
✓ Verified Correct Answers
✓ Updated 2025/2026 Psychiatric Standards
✓ Comprehensive Mental Health Coverage
✓ Board-Aligned Content Specifications
Assessment Components
175 Questions with Verified Correct Answers
Core Content Areas
Psychopharmacology & Neurobiology (30 Questions)
Psychotherapeutic Modalities (28 Questions)
Diagnosis & Assessment (25 Questions)
Clinical Management & Treatment (24 Questions)
Legal/Ethical Considerations (22 Questions)
Special Populations (22 Questions)
Health Promotion & Prevention (24 Questions)
Answer Format
Verified correct answers in bold green with:
Evidence-based treatment rationales
Diagnostic reasoning pathways
Medication management justifications
Therapeutic intervention explanations
🔹
Critical Updates 2025/2026
🔹
NEW - Updated psychopharmacology guidelines
🔹
UPDATED - Diagnostic assessment tools
REVISED - Telehealth practice standards
🔹 MODIFIED - Integrated care models
,Study Materials Include
✓ Psychopharmacology reference guides
✓ Diagnostic criteria charts
✓ Treatment algorithm references
✓ Legal/ethical decision trees
Assessment Features
✓ Timed board simulation
✓ Performance analytics by domain
✓ Customized competency recommendations
✓ Knowledge domain tracking
Psychopharmacology & Neurobiology (Questions 1–30)
Question 1: A 34-year-old female with treatment-resistant depression has failed SSRIs and
SNRIs. The PMHNP considers augmentation. Which agent has the strongest evidence for
adjunctive use in MDD per APA guidelines?
A) Lithium
B) Aripiprazole
C) T3 (liothyronine)
D) Buspirone
Rationale: FDA-approved adjunct; D2 partial agonist enhances prefrontal dopamine. STAR*D
trial; APA Practice Guideline for MDD.
Question 2: A 28-year-old male with schizophrenia on risperidone 6 mg/day develops
galactorrhea and amenorrhea. Labs: prolactin 120 ng/mL. First-line intervention?
A) Increase dose
B) Switch to aripiprazole
C) Add cabergoline
D) Continue monitoring
Rationale: Prolactin-sparing atypical; D2 partial agonism. ANCC Psychopharm.
Question 3: Mechanism of action of bupropion in depression and smoking cessation:
A) 5-HT reuptake
B) NE and DA reuptake inhibition
C) Alpha-2 antagonism
D) NMDA antagonism
Rationale: NDRI; minimal sexual side effects. Stahl’s Essential Psychopharmacology.
Question 4: A 45-year-old with bipolar I mania is on lithium 1200 mg/day. Serum level: 1.4
mEq/L. Symptoms: tremor, confusion, ataxia. Immediate action?
A) Increase dose
,B) Hold lithium, IV hydration, check renal function
C) Add valproate
D) Monitor only
Rationale: Toxicity >1.5 mEq/L; neurotoxicity. APA Bipolar Guideline.
Question 5: Clozapine monitoring: Absolute requirement before initiation and weekly for
6 months?
A) ECG
B) ANC (absolute neutrophil count)
C) LFTs
D) Lipid panel
Rationale: Agranulocytosis risk (0.8%); REMS program. FDA.
Question 6: A client on venlafaxine 300 mg/day reports BP 158/98 mmHg. Next step?
A) Discontinue immediately
B) Reduce dose, add antihypertensive if needed
C) Switch to SSRI
D) No action
Rationale: Dose-dependent hypertension; monitor BP. SNRI class effect.
Question 7: First-pass effect explains lower bioavailability of which drug when taken orally?
A) Lorazepam
B) Amitriptyline
C) Fluoxetine
D) Aripiprazole
Rationale: TCA; hepatic metabolism. Pharmacokinetics.
Question 8: A 19-year-old with ADHD starts methylphenidate. Contraindication?
A) Tics
B) Structural cardiac defect
C) Anxiety
D) Insomnia
Rationale: Sudden death risk; AHA screening. AACAP.
Question 9: Half-life of fluoxetine and norfluoxetine requires how long for full washout?
A) 1 week
B) 4–6 weeks
C) 24 hours
D) 3 days
Rationale: Longest half-life SSRI; drug interaction risk. ANCC.
Question 10: Black box warning for varenicline:
A) Seizure
, B) Neuropsychiatric symptoms (suicidality, aggression)
C) QT prolongation
D) Hepatotoxicity
Rationale: Nicotinic agonist; monitor mood. FDA.
Question 11: Paliperidone is the major active metabolite of:
A) Olanzapine
B) Risperidone
C) Quetiapine
D) Ziprasidone
Rationale: 9-hydroxyrisperidone; once-monthly IM. Psychopharm.
Question 12: Serotonin syndrome triad:
A) Bradycardia, hypotension, miosis
B) Hyperthermia, rigidity, altered mental status
C) Hyporeflexia, dry skin
D) Diarrhea only
Rationale: SSRI + MAOI; Hunter criteria. DSM-5-TR.
Question 13: CYP450 2D6 poor metabolizer increases risk of side effects with:
A) Citalopram
B) Paroxetine
C) Sertraline
D) Escitalopram
Rationale: Strong 2D6 inhibitor; dose adjustment. CPIC.
Question 14: Long-acting injectable with lowest risk of post-injection delirium/sedation
syndrome?
A) Risperidone (Risperdal Consta)
B) Aripiprazole lauroxil (Aristada)
C) Olanzapine pamoate (Zyprexa Relprevv)
D) Paliperidone palmitate (Invega Sustenna)
Rationale: No REMS monitoring required. FDA.
Question 15: Naltrexone mechanism in alcohol use disorder:
A) Dopamine agonist
B) Mu-opioid receptor antagonist
C) GABA enhancer
D) Glutamate modulator
Rationale: Reduces craving; COMBINE study. ASAM.
Question 16: Akathisia is most associated with which receptor blockade?
A) 5-HT2A
